Traders should monitor FILSPARI's commercial uptake in FSGS, as the expanded indication significantly increases the addressable market and royalty stream for Ligand; the 9% royalty on a growing sales base could drive outsized revenue growth if adoption accelerates.
Price Chart
Executive Summary
Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, marking the first approved therapy for this condition. Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI, which expands its commercial potential beyond IgA nephropathy and positions it as a key driver of future royalty growth.
Key Facts
- FDA approved FILSPARI for FSGS in patients aged 8+ without nephrotic syndrome, the first and only approved treatment for this indication.
- Ligand receives a 9% royalty on worldwide net sales of FILSPARI, which is already the most prescribed FDA-approved drug for IgA nephropathy.
- Phase 3 DUPLEX study showed a 46% reduction in proteinuria overall and 48% in non-nephrotic syndrome patients, with statistically significant results.
- Addressable U.S. population estimated at over 30,000 patients with FSGS without nephrotic syndrome.
- FILSPARI has a dual mechanism targeting endothelin A and angiotensin II receptors, offering kidney protection.
Financial Impact
High incremental royalty revenue potential from expanded indication; FILSPARI now addresses a second rare kidney disease with significant unmet need.
Risk Factors
- Commercial execution risk: Market penetration and reimbursement for the new FSGS indication may lag expectations.
- Regulatory and clinical risk: Future safety findings or label restrictions could limit use.
- Competition risk: Emerging therapies for FSGS could challenge FILSPARI's dominance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273192 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Insider Cluster | $276.98 $298.50 | ▲ +7.77% | ▲ +5.66% | $302.96 (+9.38%) |
Aug 14, 2026 7w ago | Insider Cluster | $291.77 $280.18 | ▼ −3.97% | ▼ −2.78% | $302.96 (+3.84%) |
Aug 6, 2026 8w ago | 8-K | $300.14 $288.82 | ▼ −3.77% | ▼ −4.98% | $302.96 (+0.94%) |
Jun 25, 2026 14w ago | 8-K | $303.59 $319.55 | ▲ +5.26% | ▲ +3.09% | $302.96 (−0.21%) |
Jun 18, 2026 15w ago | Insider Cluster | $274.88 $295.92 | ▲ +7.65% | ▲ +9.32% | $302.96 (+10.22%) |
Jun 16, 2026 15w ago | Insider Cluster | $255.25 $279.44 | ▲ +9.48% | ▲ +11.71% | $302.96 (+18.69%) |
Jun 12, 2026 15w ago | Insider Cluster | $253.25 $262.17 | ▲ +3.52% | ▲ +4.91% | $302.96 (+19.63%) |
May 1, 2026 22w ago | Insider Cluster | $227.44 $221.41 | ▼ −2.65% | ▼ −5.00% | $302.96 (+33.20%) |
Apr 14, 2026 24w ago | Press Release | $232.34 $226.67 | ▼ −2.44% | ▼ −3.83% | $302.96 (+30.40%) |
Feb 26, 2026 31w ago | 8-K | $196.17 $206.27 | ▲ +5.15% | ▲ +6.28% | $302.96 (+54.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access